COMPARATIVE ASSESSMENT OF PRURIFLOXACIN, SPARFLOXACIN, GATIFLOXACIN AND LEVOFLOXACIN IN THE RABBIT MODEL OF PROARRHYTHMIA
Open Access
- 1 January 2004
- journal article
- research article
- Published by Japanese Society of Toxicology in The Journal of Toxicological Sciences
- Vol. 29 (1) , 63-71
- https://doi.org/10.2131/jts.29.63
Abstract
The administration of certain quinolone antibiotics has been associated with a prolongation of the QT interval on electrocardiogram, and in rare cases ventricular arrhythmias such as torsades de pointes. In this in vivo study using a rabbit arrhythmia model, we assessed the proarrhythmic effects and changes in the QT interval elicited by the administration of NM394 (UFX), an active metabolite of the new quinolone antibiotic prulifloxacin, and three representative quinolones, sparfloxacin (SPFX), gatifloxacin (GFLX) and levofloxacin (LVFX). Chloralose-anesthetized rabbits were co-administered a continuous infusion of methoxamine (15 μg/kg/min) together with NaOH (vehicle, 0.2 mol/L), SPFX (2, 3, 4 mg/kg/min), GFLX (4 mg/kg/min), LVFX (4 mg/kg/min) or UFX (4 mg/kg/min) via the ear vein, and then the effects on electrocardiogram were examined. SPFX and GFLX both prolonged the QT and QTc intervals. GFLX also induced premature ventricular contractions in all 6 rabbits that received it, and subsequently it induced torsades de pointes (TdP) in 3 of the 6 rabbits. SPFX infused at the dose of 4 mg/kg/min induced conduction blocks without inducing TdP, whereas that infused at the lower dose of 3 mg/kg/min induced both conduction blocks and TdP. The infusions with LVFX and UFX did not elicit remarkable prolongations in the QT interval, and none of the animals infused with the agents developed arrhythmia. These findings suggested that LVFX and UFX were less potent than SPFX and GFLX in prolonging the QT interval and inducing life-threatening arrhythmias.Keywords
This publication has 17 references indexed in Scilit:
- Prulifloxacin: in vitro (HERG current) and in vivo (conscious dog) assessment of cardiac riskEuropean Journal of Pharmacology, 2003
- Rates of Torsades de Pointes Associated with Ciprofloxacin, Ofloxacin, Levofloxacin, Gatifloxacin, and MoxifloxacinPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2001
- A Comparative Study of the Fluoroquinolone Antibacterial Agents on the Action Potential Duration in Guinea Pig Ventricular Myocardia.The Japanese Journal of Pharmacology, 2001
- Fluoroquinolone Toxicity Profiles: A Review Focusing on Newer AgentsClinical Infectious Diseases, 1999
- Torsades de pointe probably related to sparfloxacinEuropean Journal of Clinical Microbiology & Infectious Diseases, 1996
- Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early afterdepolarisationsCardiovascular Research, 1993
- Clinical Features and Management of Adverse Effects of Quinolone AntibacterialsDrug Safety, 1991
- QTU-Prolongation and Torsades de Pointes Induced by Putative Class III Antiarrhythmic Agents in the RabbitJournal of Cardiovascular Pharmacology, 1990
- The Lambeth Conventions: guidelines for the study of arrhythmias in ischaemia, infarction, and reperfusionCardiovascular Research, 1988
- New Tables for Multiple Comparisons with a ControlPublished by JSTOR ,1964